VLX103, is a novel oral form of pentamidine specifically designed to target the liver and minimize exposure to non-target, non-hepatic, organs and tissues. Consequently, VLX103 can deliver therapeutically relevant intra-hepatic concentrations of pentamidine, a molecule known for its anti-inflammatory activities. This oral form avoids dose-limiting toxicity usually associated with the high systemic exposure of intravenously administered pentamidine.
Verlyx is engaged in the development of VLX103 for the treatment of diseases affecting the liver, such as Non-Alcoholic Steatohepatitis (NASH) and Alcoholic Steatohepatitis (ASH). Other indications affecting the liver, such as NAFLD, are also part of the company’s ongoing development program.
To support the development of VLX103 as the first oral form of pentamidine, rodent and non-rodent toxicology studies were conducted. Results confirmed hepatoselective properties and a safer toxicology profile based on a lower systemic exposure.